Lasolvan, also known as ambroxol, is a synthetic mucolytic drug used to treat respiratory conditions. It works by breaking down mucus, making it easier to cough up. Lasolvan is synthesized from bromhexine, another mucolytic drug, and is available in various forms, including oral tablets, syrup, and nebulizer solutions. Its mechanism of action involves stimulating the production of surfactant, a substance that helps to reduce surface tension in the lungs and improve airflow. Lasolvan is commonly used for conditions such as acute and chronic bronchitis, pneumonia, and cystic fibrosis. It is also used to prevent respiratory distress syndrome in premature infants. Researchers are interested in exploring the potential benefits of Lasolvan for other conditions, such as Alzheimer's disease and cancer, due to its effects on neuroprotection and inflammation. Lasolvan is generally well-tolerated, but some common side effects may include nausea, vomiting, and diarrhea. However, it should not be used by people with certain medical conditions, such as liver disease or severe kidney disease. Lasolvan is available by prescription in many countries and is widely studied due to its effectiveness and safety profile in treating respiratory conditions.'
| ID Source | ID |
|---|---|
| PubMed CID | 108013 |
| CHEMBL ID | 1514634 |
| CHEBI ID | 31198 |
| SCHEMBL ID | 99455 |
| MeSH ID | M0000856 |
| Synonym |
|---|
| AC-024 |
| 4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol |
| MLS002153788 |
| ponophen |
| lasolvan |
| mucosolvan |
| mucoangin |
| na-872 |
| exr-202 |
| lazolvan |
| na-872et |
| mucosolvan-l |
| mucosal-l |
| (e)-4-hdmb |
| einecs 245-899-2 |
| ambroxol lozenge |
| cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)-, hydrochloride, trans- |
| trans-4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexan-1-ol hydrochloride |
| cyclohexanol, 4-(n-(2-amino-3,5-dibromobenzyl)amino)-, hydrochloride (e)- |
| na 872 hydrochloride |
| ambroxol hydrochloride [jan] |
| ambroxol (hydrochloride) |
| mucolear |
| cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, monohydrochloride, trans- |
| trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride |
| PRESTWICK_717 |
| ambroxol hydrochloride |
| cas-23828-92-4 |
| smr000875269 |
| MLS001333105 |
| MLS001333106 |
| 23828-92-4 |
| hustless (tn) |
| ambroxol hydrochloride (jan) |
| D01479 |
| NCGC00094999-01 |
| NCGC00094999-02 |
| NCGC00092387-01 |
| SPECTRUM1503080 |
| HMS1922C19 |
| HMS1569I13 |
| NCGC00016781-04 |
| ambroxol hcl |
| trans-4-[[(2-amino-3,5-dibromo-phenyl)methyl]amino]-cyclohexanol hydrochloride |
| A816928 |
| trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride |
| nsc-758224 |
| BCP9000284 |
| nsc758224 |
| pharmakon1600-01503080 |
| ambroxolhydrochloride |
| dtxcid0025442 |
| tox21_110607 |
| dtxsid2045442 , |
| AKOS015951294 |
| CCG-39174 |
| NCGC00016781-03 |
| nsc 758224 |
| cc995zmv90 , |
| unii-cc995zmv90 |
| ccris 8686 |
| BCP0726000073 |
| FT-0630506 |
| AKOS015895175 |
| ambroxol hydrochloride [ep monograph] |
| ambroxol hydrochloride [who-dd] |
| ambroxol hydrochloride [mi] |
| ambroxol hydrochloride [mart.] |
| ambroxol hydrochloride [ep impurity] |
| S3064 |
| CCG-220366 |
| 15942-05-9 |
| SCHEMBL99455 |
| KS-5248 |
| CHEMBL1514634 |
| AKOS024462505 |
| cis-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride |
| F1131-0002 |
| 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol hydrochloride |
| ambroxol hydrochloride |
| trans-4-[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexanol hydrochloride |
| Q-100980 |
| cis-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride |
| ambroxol hydrochloride, 98% |
| mfcd00078932 |
| 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydrochloride |
| ambroxol hydrochloride, analytical standard |
| ambroxol hydrochloride, european pharmacopoeia (ep) reference standard |
| SR-01000837516-3 |
| sr-01000837516 |
| sr-05000001463 |
| SR-05000001463-2 |
| (1r,4r)-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol hydrochloride |
| 4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride, aldrichcpr |
| 1146648-86-3 |
| HY-B1039A |
| CS-0013219 |
| ambroxol hydrochloride 1.0 mg/ml in methanol (as free base) |
| 1384955-66-1 |
| ambroxol hydrochloride imp. d (ep); ambroxol imp. d (ep); cis-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride; ambroxol hydrochloride imp. d (ep) as hydrochloride; ambroxol hydrochloride impurity d as hydrochloride; ambroxol impurity d as h |
| CHEBI:31198 |
| QNVKOSLOVOTXKF-UHFFFAOYSA-N |
| SW198832-2 |
| BCP04490 |
| cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, hydrochloride |
| SY052506 |
| cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, hydrochloride (1:1), trans- |
| 4-(2-amino-3,5-dibromobenzylamino)cyclohexanol hydrochloride |
| (1r,4r)-4-(2-amino-3,5-dibromobenzylamino)cyclohexanol hydrochloride |
| ambroxol hydrochloride ,(s) |
| DTXSID60936098 |
| 4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol--hydrogen chloride (1/1) |
| ambroxol hydrochloride 100 microg/ml in acetonitrile |
| trans-4-(2-amino-3,5-dibromobenzylamino)cyclohexanol hydrochloride |
| ambroxol impurity d hydrochloride |
| imp. d (ep): cis-4-[(2-amino-3,5-dibromobenzyl)amino]-cyclohexanol hcl |
| A16398 |
| H11915 |
| Q27275396 |
| ambroxol impurity d hcl |
| trans-4-((2-amino-3,5-dibromobenzyl)-amino)cyclohexanol hydrochloride |
| r3593uz7hs , |
| ambroxol hydrochloride, cis- |
| cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, hydrochloride (1:1), cis- |
| unii-r3593uz7hs |
| BA166015 |
| cyclohexanol,4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-,hydrochloride |
| trans-4-((2-amino-3,5-dibromobenzyl)amino)-cyclohexanol hydrochloride |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 7.0795 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.3548 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 23.7246 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 4.7391 | 0.0002 | 21.2231 | 8,912.5098 | AID743036; AID743040; AID743053 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 10.0000 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 6.0070 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 125.8920 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 23.3667 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 12.5893 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| iron ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| calcium ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| protein binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| lipid binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 13S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 8(S)-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 15-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 9S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.06) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||